(CercleFinance.com) – Pharnext announces this evening that it has issued a seventh tranche of 350 bonds convertible into shares (OCA) with a nominal value of 10,000 euros each, under a contract concluded with the company Global Tech Opportunities 13.
The funds paid as part of this financing will mainly be used to finance the PREMIER trial, a pivotal Phase III clinical study of PXT3003, the Company’s main product, in Charcot-Marie-Tooth disease type 1A, and the open-label Phase III extension study.